Jefferies Group LLC reissued their buy rating on shares of Verona Pharma Plc (LON:VRP) in a research note released on Wednesday morning. Jefferies Group LLC currently has a GBX 250 ($3.29) target price on the stock.

Separately, N+1 Singer reaffirmed a buy rating on shares of Verona Pharma Plc in a report on Tuesday, November 7th. Five investment analysts have rated the stock with a buy rating, The company currently has an average rating of Buy and a consensus price target of GBX 80.75 ($1.06).

Shares of Verona Pharma Plc (LON VRP) opened at GBX 120 ($1.58) on Wednesday. Verona Pharma Plc has a 1-year low of GBX 100 ($1.32) and a 1-year high of GBX 199.50 ($2.62).

ILLEGAL ACTIVITY WARNING: “Verona Pharma Plc (VRP) Given Buy Rating at Jefferies Group LLC” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/11/12/verona-pharma-plc-vrp-given-buy-rating-at-jefferies-group-llc.html.

About Verona Pharma Plc

Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company’s product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.

Analyst Recommendations for Verona Pharma Plc (LON:VRP)

Receive News & Ratings for Verona Pharma Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma Plc and related companies with MarketBeat.com's FREE daily email newsletter.